Domov › Nemalobunkový karcinóm pľúc › Oklahoma
Klinické štúdie Nemalobunkový karcinóm pľúc v štáte Oklahoma
31 štúdií pre Nemalobunkový karcinóm pľúc hľadá účastníkov v zariadeniach v štáte Oklahoma.
Mestá v štáte Oklahoma
Oficiálny text štúdie (anglicky)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
- a 1 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT04267848The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
Prebieha náborFáza 1/2
Vek 12 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT04585750Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT07388524Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06498635A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Local Institution - 0418, Oklahoma City
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07361510A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Hightower Clinical, LLC ( Site 0084), Oklahoma City
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06312137Pan-tumor MRD Study
- Oklahoma Cancer Specialists and Research Institute (OCSRI), Tulsa
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06605404Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT03191149Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- INTEGRIS Cancer Institute of Oklahoma, Oklahoma City
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06712316Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06128551Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Oklahoma City
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 9. 2026 · NCT06767514FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- OU Health Stephenson Cancer Center, Oklahoma City
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT06303505A Phase 1/1b Study of IAM1363 in HER2 Cancers
- OU Health Stephenson Cancer Center, Oklahoma City
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT06253871Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 8. 2026 · NCT06500481Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- University of Oklahoma - Health Sciences Center, Oklahoma City
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 8. 2026 · NCT05579366Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 7. 2026 · NCT06686771A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 6. 7. 2026 · NCT04389632Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - OKC, Oklahoma City
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 6. 2026 · NCT07327489Study of XB010 in Subjects With Solid Tumors
- Stephenson Cancer Center, Oklahoma City
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 6. 2026 · NCT06545331KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- OU Stephenson Cancer Center, Oklahoma City
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 8. 6. 2026 · NCT06026410Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 6. 2026 · NCT05642572Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 19. 5. 2026 · NCT05431270Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 6. 5. 2026 · NCT06116682Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
Prebieha náborFáza 2
18 Minutes · Všetky pohlavia · Aktualizované 5. 5. 2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Southwest Medical Center, Oklahoma City
- a 1 ďalších
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 5. 2026 · NCT06616584Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Mercy Hospital Oklahoma City, Oklahoma City
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 3. 2026 · NCT06418204GEMINI-NSCLC: NSCLC Biomarker Study
- Hightower Clinical, Oklahoma City
- Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
- Oklahoma Cancer Specialists and Research Institute, Tulsa
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 2. 2026 · NCT05236114A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Oklahoma City
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 7. 1. 2026 · NCT06999187SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
Prebieha náborObservačná štúdia
Všetky vekové kategórie · Všetky pohlavia · Aktualizované 28. 10. 2025 · NCT03452774A Study of NX-1607 in Adults With Advanced Malignancies
- University of Oklahoma, Oklahoma City
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2025 · NCT05107674BostonGene and Exigent Genomic INsight Study
- Oklahoma Cancer Specialists and Research Institute, Tulsa
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 2. 2025 · NCT06272864Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.